Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Generali Asset Management SPA SGR

Key Points

• Generali Asset Management SPA SGR increased its stake in Regeneron Pharmaceuticals by 15% during Q2, owning 12,684 shares valued at approximately $6.66 million.
• Analysts have issued mixed ratings on Regeneron, with three giving it a "Strong Buy," and a consensus average price target of $817.88.
• Regeneron recently reported Q2 earnings per share of $12.89, significantly exceeding expectations, alongside a revenue increase to $3.68 billion.

Generali Asset Management SPA SGR lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 15.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,684 shares of the biopharmaceutical company's stock after purchasing an additional 1,650 shares during the quarter. Generali Asset Management SPA SGR's holdings in Regeneron Pharmaceuticals were worth $6,659,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Nuveen LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth about $343,764,000. Pacer Advisors Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after acquiring an additional 390,374 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 18.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after acquiring an additional 174,056 shares during the period. Vanguard Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after acquiring an additional 121,545 shares during the period. Finally, Retirement Systems of Alabama grew its holdings in shares of Regeneron Pharmaceuticals by 476.4% in the 1st quarter. Retirement Systems of Alabama now owns 131,382 shares of the biopharmaceutical company's stock worth $83,326,000 after acquiring an additional 108,589 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on REGN. Argus lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a "buy" rating and a $890.00 price objective on the stock. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Canaccord Genuity Group reiterated a "buy" rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Finally, Citigroup increased their price target on shares of Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a "buy" rating in a research report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $817.88.

Regeneron Pharmaceuticals Stock Up 0.7%

Shares of NASDAQ REGN opened at $576.42 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,020.55. The firm's 50 day moving average price is $574.15 and its 200 day moving average price is $563.61. The firm has a market cap of $61.09 billion, a P/E ratio of 14.53, a price-to-earnings-growth ratio of 1.84 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter last year, the firm earned $11.56 earnings per share. The business's revenue was up 3.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.